Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: One cycle Clear all
Terminated Phase 1 Interventional

Wild Type p53 Adenovirus for Oral Premalignancies

NCT00410865
View directory record Official record
Conditions
Mouth Cancer
Interventions
INGN 201
Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 30, 2026, 7:32 AM EDT
Completed No phase listed Observational

Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics

NCT03947099
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Anxiety Disorders
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Klarisana Physician Services PLLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 30, 2026, 7:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Metoclopramide Versus Placebo for GJ Placement

NCT03331965
View directory record Official record
Conditions
Radiation Exposure, Enteral Nutrition
Interventions
Metoclopramide 5 MG/ML Injectable Solution, Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 30, 2026, 7:32 AM EDT
Terminated Not applicable Interventional Results available

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

NCT01758328
View directory record Official record
Conditions
Multiple Myeloma
Interventions
busulfan, melphalan, fludarabine, anti-thymocyte globulin (ATG), a T cell depleted stem cell transplant
Drug · Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 72 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 7:32 AM EDT
Recruiting Phase 2 Interventional

TRUDI: TDXD+Durva in HER2+/Low IBC

NCT05795101
View directory record Official record
Conditions
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

NCT04132336
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients

NCT00420771
View directory record Official record
Conditions
Benzodiazepine Dependence, Opioid Dependence
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Long Island City, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 7:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas

NCT01721577
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma
Interventions
AXL1717
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 30, 2026, 7:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

NCT03610282
View directory record Official record
Conditions
Anesthesia
Interventions
IV Methylphenidate, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 30, 2026, 7:32 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510
View directory record Official record
Conditions
Effect of Drug
Interventions
Aspirin 325mg
Drug
Lead sponsor
Hematology Oncology Associates of Central New York
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

NCT00133991
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Filgrastim, Rituximab, Cyclophosphamide, Cytarabine, Methotrexate, Prednisone, Hydrocortisone, Vincristine, Leucovorin
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
30 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 30, 2026, 7:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT05278208
View directory record Official record
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418
View directory record Official record
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897
View directory record Official record
Conditions
Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions
THOR-707, Pembrolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 7:32 AM EDT
Terminated Phase 1 Interventional

OSI-906 and Irinotecan in Patients With Advanced Cancer

NCT01016860
View directory record Official record
Conditions
Colorectal Cancer
Interventions
OSI-906, irinotecan
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 30, 2026, 7:32 AM EDT
Recruiting Phase 1 Interventional

HNC: Human Neural Circuits Electrophysiology During Cognition

NCT05962424
View directory record Official record
Conditions
Psychiatric Disorder
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

NCT02800785
View directory record Official record
Conditions
Appendicitis
Interventions
Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Continuation Therapy in Advanced NSCLC

NCT03083808
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 30, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

NCT02458014
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
Interventions
Blinatumomab, TKI
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 7:32 AM EDT